{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T13:10:17Z","timestamp":1736255417766,"version":"3.32.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03675-w","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T11:14:10Z","timestamp":1736248450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with therapeutic response to adalimumab in hidradenitis suppurativa: evidence from the Belgian patients of the European Registry for Hidradenitis Suppurativa (ERHS-Be)"],"prefix":"10.1007","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4188-1986","authenticated-orcid":false,"given":"Mathieu","family":"Daoud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4533-8297","authenticated-orcid":false,"given":"Farida","family":"Benhadou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9266-0342","authenticated-orcid":false,"given":"Mariano","family":"Suppa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9352-5284","authenticated-orcid":false,"given":"Anne-Sophie","family":"Sarkis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Heudens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8392-0658","authenticated-orcid":false,"given":"Lila","family":"Desmarest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassane","family":"Njimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4506-6989","authenticated-orcid":false,"given":"Mathilde","family":"Daxhelet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Nobile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalila","family":"Karama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7164-2658","authenticated-orcid":false,"given":"Jonathan M.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0712-2540","authenticated-orcid":false,"given":"Gregor B. E.","family":"Jemec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-0667","authenticated-orcid":false,"given":"V\u00e9ronique","family":"del Marmol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"issue":"1","key":"3675_CR1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/bjd.20656","volume":"186","author":"JML White","year":"2022","unstructured":"White JML, Lui H, Chute CG, Jakob R, Chalmers RJG (2022) The WHO ICD-11 classification of dermatological diseases: a new comprehensive online skin disease taxonomy designed by and for dermatologists. Br J Dermatol 186(1):178\u20139","journal-title":"Br J Dermatol"},{"key":"3675_CR2","unstructured":"ED92.0 Hidradenitis suppurativa - ICD-11 MMS [Internet]. [cit\u00e9 4 nov 2023]. Disponible sur: https:\/\/www.findacode.com\/icd-11\/code-1621794154.html"},{"issue":"1","key":"3675_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4161\/derm.2.1.12490","volume":"2","author":"S Fimmel","year":"2010","unstructured":"Fimmel S, Zouboulis CC (2010) Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol 2(1):9\u201316","journal-title":"Dermatoendocrinol"},{"issue":"5","key":"3675_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1159\/000507348","volume":"236","author":"M Daxhelet","year":"2020","unstructured":"Daxhelet M, Suppa M, White J, Benhadou F, Thorlacius LR, Jemec GBE et al (2020) Proposed definitions of typical lesions in hidradenitis suppurativa. Dermatol Basel Switz 236(5):431","journal-title":"Dermatol Basel Switz"},{"key":"3675_CR5","doi-asserted-by":"publisher","unstructured":"Matusiak \u0141 (2020) Profound consequences of hidradenitis suppurativa: a review. Br J Dermatol [Internet]. 9 mai 2018 [cit\u00e9 11 nov 2020]; Disponible sur: http:\/\/doi.wiley.com\/https:\/\/doi.org\/10.1111\/bjd.16603","DOI":"10.1111\/bjd.16603"},{"key":"3675_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CCID.S111019","volume":"10","author":"M Napolitano","year":"2017","unstructured":"Napolitano M, Megna M, Timoshchuk EA, Patruno C, Balato N, Fabbrocini G et al (2017) Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol 10:105\u2013115","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"3675_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat R, Jemec GBE, Matusiak \u0141, Kimball AB, Prens E, Wolk K (2020) Hidradenitis suppurativa. Nat Rev Dis Primer 6(1):18","journal-title":"Nat Rev Dis Primer"},{"issue":"8","key":"3675_CR8","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.3390\/cells10082094","volume":"10","author":"E Scala","year":"2021","unstructured":"Scala E, Cacciapuoti S, Garzorz-Stark N, Megna M, Marasca C, Seiringer P et al (2021) Hidradenitis suppurativa: where we are and where we are going. Cells 10(8):2094","journal-title":"Cells"},{"issue":"22","key":"3675_CR9","doi-asserted-by":"publisher","first-page":"8436","DOI":"10.3390\/ijms21228436","volume":"21","author":"E Del Duca","year":"2020","unstructured":"Del Duca E, Morelli P, Bennardo L, Di Raimondo C, Nistic\u00f2 SP (2020) Cytokine pathways and investigational target therapies in hidradenitis suppurativa. Int J Mol Sci 21(22):8436","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3675_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/cei.13449","volume":"201","author":"JM Fletcher","year":"2020","unstructured":"Fletcher JM, Moran B, Petrasca A, Smith CM (2020) IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa. Clin Exp Immunol 201(2):121\u2013134","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"3675_CR11","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/jdv.17779","volume":"36","author":"Z Dajnoki","year":"2022","unstructured":"Dajnoki Z, Somogyi O, Medgyesi B, Jenei A, Szab\u00f3 L, G\u00e1sp\u00e1r K et al (2022) Primary alterations during the development of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 36(3):462\u2013471","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"3675_CR12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jaad.2019.08.089","volume":"82","author":"SR Goldburg","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ (2020) Hidradenitis suppurativa: current and emerging treatments. J Am Acad Dermatol 82(5):1061\u20131082","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"3675_CR13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC et al (2016) Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 375(5):422\u201334","journal-title":"N Engl J Med"},{"issue":"1","key":"3675_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","volume":"80","author":"CC Zouboulis","year":"2018","unstructured":"Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C et al (2018) Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol 80(1):60-69.e2","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3675_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1346-8138.15605","volume":"48","author":"A Morita","year":"2021","unstructured":"Morita A, Takahashi H, Ozawa K, Imafuku S, Takekuni N, Takahashi K et al (2021) Long-term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: open-label phase 3 results. J Dermatol 48(1):3\u201313","journal-title":"J Dermatol"},{"issue":"5","key":"3675_CR16","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jid.2020.10.014","volume":"141","author":"JS Kirby","year":"2021","unstructured":"Kirby JS (2021) Unraveling the heterogeneity of hidradenitis suppurativa with phenotype schema. J Invest Dermatol 141(5):1136\u20138","journal-title":"J Invest Dermatol"},{"issue":"5","key":"3675_CR17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.clindermatol.2023.08.016","volume":"41","author":"NDK Koerts","year":"2023","unstructured":"Koerts NDK, Bouwman K, Prens LM, Horv\u00e1th B (2023) Assessment tools and phenotype classification for hidradenitis suppurativa. Clin Dermatol 41(5):601\u2013610","journal-title":"Clin Dermatol"},{"key":"3675_CR18","doi-asserted-by":"publisher","first-page":"1145152","DOI":"10.3389\/fmed.2023.1145152","volume":"10","author":"M Daoud","year":"2023","unstructured":"Daoud M, Suppa M, Benhadou F, Daxhelet M, Njimi H, White J et al (2023) Overview and comparison of the clinical scores in hidradenitis suppurativa: a real-life clinical data. Front Med 10:1145152","journal-title":"Front Med"},{"key":"3675_CR19","doi-asserted-by":"publisher","first-page":"918858","DOI":"10.3389\/fgene.2022.918858","volume":"13","author":"G Vellaichamy","year":"2022","unstructured":"Vellaichamy G, Amin AT, Dimitrion P, Hamzavi Z, Zhou L, Adrianto I et al (2022) Recent advances in hidradenitis suppurativa: role of race, genetics, and immunology. Front Genet 13:918858","journal-title":"Front Genet"},{"issue":"4","key":"3675_CR20","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/bjd.20097","volume":"185","author":"Y Cao","year":"2021","unstructured":"Cao Y, Hong F, Conlon DM, Sidur L, Smith KM, Fang Y et al (2021) Potential predictive biomarkers of adalimumab response in patients with hidradenitis suppurativa. Br J Dermatol 185(4):804\u2013814","journal-title":"Br J Dermatol"},{"issue":"2","key":"3675_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00403-020-02149-z","volume":"314","author":"L Thorlacius","year":"2022","unstructured":"Thorlacius L, Riis PT, List EK, Christensen R, Jemec GBE (2022) Sub-classification of hidradenitis suppurativa: a cross-sectional study. Arch Dermatol Res 314(2):207\u201312","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"3675_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/bjd\/ljac033","volume":"188","author":"MM Okun","year":"2023","unstructured":"Okun MM (2023) The promise of personalized medicine for hidradenitis suppurativa. Br J Dermatol 188(1):3","journal-title":"Br J Dermatol"},{"issue":"1","key":"3675_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/bjd.18983","volume":"184","author":"AV Marzano","year":"2021","unstructured":"Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G et al (2021) Evidence for a \u00ab\u202fwindow of opportunity\u202f\u00bb in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol 184(1):133\u2013140","journal-title":"Br J Dermatol"},{"issue":"8","key":"3675_CR24","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1111\/jdv.13267","volume":"30","author":"M Daxhelet","year":"2016","unstructured":"Daxhelet M, Suppa M, Benhadou F, Djamei V, Tzellos T, Ingvarsson G et al (2016) Establishment of a European Registry for hidradenitis suppurativa\/acne inversa by using an open source software. J Eur Acad Dermatol Venereol JEADV 30(8):1424\u20136","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"4","key":"3675_CR25","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1111\/jdv.17023","volume":"35","author":"M Daxhelet","year":"2021","unstructured":"Daxhelet M, Daoud M, Suppa M, Benhadou F, Njimi H, Tzellos T et al (2021) European registry for hidradenitis suppurativa: state of play. J Eur Acad Dermatol Venereol JEADV 35(4):e274-6","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"3675_CR26","unstructured":"Accueil | INAMI [Internet]. [cit\u00e9 28 juill 2024]. Disponible sur: https:\/\/www.inami.fgov.be\/fr"},{"issue":"6","key":"3675_CR27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/jdv.13216","volume":"30","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M et al (2016) HiSCR (hidradenitis suppurativa clinical response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol JEADV 30(6):989\u201394","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"2","key":"3675_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/jdv.18632","volume":"37","author":"T Tzellos","year":"2022","unstructured":"Tzellos T, van Straalen KR, Kyrgidis A, Alavi A, Goldfarb N, Gulliver W et al (2022) Development and validation of IHS4\u201355, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol JEADV 37(2):395","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"4","key":"3675_CR29","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1111\/jdv.17022","volume":"35","author":"M Daoud","year":"2021","unstructured":"Daoud M, Njimi H, Benhadou F, Suppa M, Daxhelet M, Karama J et al (2021) Metascoring hidradenitis suppurativa. J Eur Acad Dermatol Venereol 35(4):e272\u2013e274","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3675_CR30","unstructured":"Hurley HJ (1989) Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus: surgical approach. Dermatol Surg. 1989; 729\u201139"},{"issue":"2","key":"3675_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0151-9638(07)91613-0","volume":"134","author":"J Revuz","year":"2007","unstructured":"Revuz J (2007) Modifications to the sartorius score and instructions for evaluating the severity of suppurative hidradenitis. Ann Dermatol Venereol 134(2):173\u2013174","journal-title":"Ann Dermatol Venereol"},{"key":"3675_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18707","author":"M Daoud","year":"2022","unstructured":"Daoud M, Benhadou F, Njimi H, Jemec GBE, Daxhelet M, White J et al (2022) Scoring hidradenitis suppurativa: how to simplify data collection? J Eur Acad Dermatol Venereol JEADV. https:\/\/doi.org\/10.1111\/jdv.18707","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"6","key":"3675_CR33","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/jid.2012.472","volume":"133","author":"F Canoui-Poitrine","year":"2013","unstructured":"Canoui-Poitrine F, Le Thuaut A, Revuz JE, Viallette C, Gabison G, Poli F et al (2013) Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol 133(6):1506\u20131511","journal-title":"J Invest Dermatol"},{"issue":"6","key":"3675_CR34","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/jdv.16183","volume":"34","author":"A Martorell","year":"2020","unstructured":"Martorell A, Jfri A, Koster SBL, Gomez-Palencia P, Solera M, Alfaro-Rubio A et al (2020) Defining hidradenitis suppurativa phenotypes based on the elementary lesion pattern: results of a prospective study. J Eur Acad Dermatol Venereol 34(6):1309\u20131318","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3675_CR35","first-page":"1","volume":"14","author":"K Dudink","year":"2021","unstructured":"Dudink K, Aarts P, Ardon C, Vossen A, Koster S, Bosch J et al (2021) Prevalence and clinical characteristics of hidradenitis suppurativa phenotypes in a large dutch cohort. Dermatology 14:1\u20133","journal-title":"Dermatology"},{"issue":"8","key":"3675_CR36","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/ced.12655","volume":"40","author":"H Naasan","year":"2015","unstructured":"Naasan H, Affleck A (2015) Atypical hidradenitis suppurativa. Clin Exp Dermatol 40(8):891\u2013893","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"3675_CR37","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2340\/00015555-2513","volume":"97","author":"B Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th B, Janse IC, Blok JL, Driessen RJB, Boer J, Mekkes JR et al (2017) Hurley staging refined: a proposal by the dutch hidradenitis suppurativa expert group. Acta Derm Venereol 97(3):412\u20133","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"3675_CR38","doi-asserted-by":"publisher","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","volume":"157","author":"AB Kimball","year":"2012","unstructured":"Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R et al (2012) Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 157(12):846\u201355","journal-title":"Ann Intern Med"},{"issue":"5 Suppl 1","key":"3675_CR39","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jaad.2015.07.047","volume":"73","author":"HH van der Zee","year":"2015","unstructured":"van der Zee HH, Jemec GBE (2015) New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes. J Am Acad Dermatol 73(5 Suppl 1):S23-26","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"3675_CR40","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/1744666X.2016.1221762","volume":"12","author":"CC Zouboulis","year":"2016","unstructured":"Zouboulis CC (2016) Adalimumab for the treatment of hidradenitis suppurativa\/acne inversa. Expert Rev Clin Immunol 12(10):1015\u20131026","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"3675_CR41","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/ced.14127","volume":"45","author":"RD Caposiena Caro","year":"2020","unstructured":"Caposiena Caro RD, Cannizzaro MV, Tartaglia C, Bianchi L (2020) Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab. Clin Exp Dermatol 45(4):438\u2013444","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"3675_CR42","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","volume":"147","author":"K Navrazhina","year":"2021","unstructured":"Navrazhina K, Frew JW, Gilleaudeau P, Sullivan-Whalen M, Garcet S, Krueger JG (2021) Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa. J Allergy Clin Immunol 147(6):2213\u20132224","journal-title":"J Allergy Clin Immunol"},{"key":"3675_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.603281","volume":"8","author":"JW Frew","year":"2021","unstructured":"Frew JW, Singh N, Jiang CS, Vaughan R, Krueger JG (2021) The Impact of body mass index upon the efficacy of adalimumab in hidradenitis suppurativa. Front Med 8:603281","journal-title":"Front Med"},{"issue":"2","key":"3675_CR44","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/ced.14448","volume":"46","author":"JW Frew","year":"2021","unstructured":"Frew JW, Jiang CS, Singh N, Grand D, Navrazhina K, Vaughan R et al (2021) Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab. Clin Exp Dermatol 46(2):306\u2013313","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"3675_CR45","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1159\/000530664","volume":"239","author":"M Daoud","year":"2023","unstructured":"Daoud M, Suppa M, Heudens S, Daxhelet M, Njimi H, Nobile L et al (2023) Treatment of acne with isotretinoin should be avoided in patients with hidradenitis suppurativa \u00ab\u202fconglobata phenotype\u202f\u00bb. Dermatol Basel Switz 239(5):738\u2013745","journal-title":"Dermatol Basel Switz"},{"issue":"1","key":"3675_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.annder.2018.10.018","volume":"146","author":"J Revuz","year":"2019","unstructured":"Revuz J, Poli F (2019) Acne conglobata: fact or fiction? Ann Dermatol Venereol 146(1):1\u20133","journal-title":"Ann Dermatol Venereol"},{"issue":"4","key":"3675_CR47","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/ced.12540","volume":"40","author":"ZZN Yiu","year":"2015","unstructured":"Yiu ZZN, Madan V, Griffiths CEM (2015) Acne conglobata and adalimumab: use of tumour necrosis factor-\u03b1 antagonists in treatment-resistant acne conglobata, and review of the literature. Clin Exp Dermatol 40(4):383\u2013386","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"3675_CR48","doi-asserted-by":"publisher","first-page":"240","DOI":"10.23736\/S2784-8671.21.07049-3","volume":"157","author":"RD Caposiena Caro","year":"2022","unstructured":"Caposiena Caro RD, Chiricozzi A, Sechi A, Molinelli E, Venturini M, Candi E et al (2022) Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa: real-life data. Ital J Dermatol Venereol 157(3):240\u2013246","journal-title":"Ital J Dermatol Venereol"},{"key":"3675_CR49","unstructured":"Grau-P\u00e9rez M, Ciudad C, Campos M, Molina A, Haselgruber S, Martorell A, et al. (2024) ADOLESBIOHS: A real-world multicentre retrospective study on the effectiveness, safety, and dosage of Adalimumab in adolescents with hidradenitis suppurativa. Oral communication pr\u00e9sent\u00e9 \u00e0: 13th conference of the European Hidradenitis Suppurativa Foundation (EHSF); 2024 Lyon."},{"issue":"5","key":"3675_CR50","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jaad.2019.12.044","volume":"82","author":"JW Frew","year":"2020","unstructured":"Frew JW, Jiang CS, Singh N, Grand D, Navrazhina K, Vaughan R et al (2020) Clinical response rates, placebo response rates and significantly associated covariates are dependent upon choice of outcome measure in hidradenitis suppurativa: a post-hoc analysis of PIONEER 1 and 2 individual patient data. J Am Acad Dermatol 82(5):1150\u20131157","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"3675_CR51","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.2340\/00015555-3520","volume":"100","author":"A Chiricozzi","year":"2020","unstructured":"Chiricozzi A, Giovanardi G, Garcovich S, Malvaso D, Caldarola G, Fossati B et al (2020) Clinical and ultrasonographic profile of adalimumab-treated hidradenitis suppurativa patients: a real-life monocentric experience. Acta Derm Venereol 100(13):5775","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"3675_CR52","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1111\/jdv.17598","volume":"35","author":"W Gulliver","year":"2021","unstructured":"Gulliver W, Alavi A, Wiseman MC, Gooderham MJ, Rao J, Alam MS et al (2021) Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study. J Eur Acad Dermatol Venereol JEADV 35(12):2431\u20139","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"1","key":"3675_CR53","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bjd.18655","volume":"182","author":"JS Kirby","year":"2020","unstructured":"Kirby JS, Moore B, Leiphart P, Shumaker K, Mammis-Gierbolini A, Benhadou F et al (2020) A narrative review of the definition of \u00ab\u202fflare\u202f\u00bb in hidradenitis suppurativa. Br J Dermatol 182(1):24\u201328","journal-title":"Br J Dermatol"},{"issue":"5","key":"3675_CR54","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/bjd.21647","volume":"187","author":"TM LeWitt","year":"2022","unstructured":"LeWitt TM, Mammis-Gierbolini A, Parnell M, Sarfo A, Paek SY, Benhadou F et al (2022) International consensus definition of disease flare in hidradenitis suppurativa. Br J Dermatol 187(5):785\u2013787","journal-title":"Br J Dermatol"},{"key":"3675_CR55","doi-asserted-by":"publisher","unstructured":"Aarts P, van\u00a0Huijstee JC, van der\u00a0Zee HH, van\u00a0Straalen KR, Prens EP (2024) Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa. J Eur Acad Dermatol Venereol [Internet]. [cit\u00e9 20 f\u00e9vr 2024];n\/a(n\/a). Disponible sur: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1111\/jdv.19725","DOI":"10.1111\/jdv.19725"},{"issue":"2","key":"3675_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031810","volume":"7","author":"R Sabat","year":"2012","unstructured":"Sabat R, Chanwangpong A, Schneider-Burrus S, Metternich D, Kokolakis G, Kurek A et al (2012) Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One 7(2):e31810","journal-title":"PLoS One"},{"issue":"4","key":"3675_CR57","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","volume":"161","author":"K Sartorius","year":"2009","unstructured":"Sartorius K, Emtestam L, Jemec GBE, Lapins J (2009) Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 161(4):831\u2013839","journal-title":"Br J Dermatol"},{"issue":"1","key":"3675_CR58","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/bjd.13864","volume":"174","author":"V Bettoli","year":"2016","unstructured":"Bettoli V, Naldi L, Cazzaniga S, Zauli S, Atzori L, Borghi A et al (2016) Overweight, diabetes and disease duration influence clinical severity in hidradenitis suppurativa-acne inversa: evidence from the national Italian registry. Br J Dermatol 174(1):195\u2013197","journal-title":"Br J Dermatol"},{"key":"3675_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000541052","volume":"11","author":"M Daoud","year":"2024","unstructured":"Daoud M, Suppa M, Benhadou F, Heudens S, Sarkis AS, Njimi H et al (2024) Factors associated with severe hidradenitis suppurativa, using hurley staging and metascore. Dermatology 11:1\u201319","journal-title":"Dermatology"},{"issue":"6","key":"3675_CR60","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/ijd.16565","volume":"62","author":"A Nosrati","year":"2023","unstructured":"Nosrati A, Torpey ME, Shokrian N, Ch\u2019en PY, Andriano TM, Benesh G et al (2023) Adalimumab efficacy is inversely correlated with body mass index (BMI) in hidradenitis suppurativa. Int J Dermatol 62(6):764\u20139","journal-title":"Int J Dermatol"},{"issue":"3","key":"3675_CR61","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/bjd.14888","volume":"176","author":"J Zweegers","year":"2017","unstructured":"Zweegers J, Roosenboom B, van de Kerkhof PCM, van den Reek JMPA, Otero ME, Atalay S et al (2017) Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort. Br J Dermatol 176(3):786\u2013793","journal-title":"Br J Dermatol"},{"issue":"2","key":"3675_CR62","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bjd.14552","volume":"175","author":"J Zweegers","year":"2016","unstructured":"Zweegers J, van den Reek JMPA, van de Kerkhof PCM, Otero ME, Kuijpers ALA, Koetsier MIA et al (2016) Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol 175(2):340\u2013347","journal-title":"Br J Dermatol"},{"issue":"2","key":"3675_CR63","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1684\/ejd.2014.2278","volume":"24","author":"RF Lafuente-Urrez","year":"2014","unstructured":"Lafuente-Urrez RF, P\u00e9rez-Pelegay J (2014) Impact of obesity on the effectiveness of adalimumab for the treatment of psoriasis: a retrospective study of 30 patients in daily practice. Eur J Dermatol EJD 24(2):217\u2013223","journal-title":"Eur J Dermatol EJD"},{"issue":"5","key":"3675_CR64","doi-asserted-by":"publisher","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Singh AG, Casteele NV, Zarrinpar A, Prokop LJ et al (2018) Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One 13(5):e0195123","journal-title":"PLoS One"},{"issue":"3","key":"3675_CR65","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04946.x","volume":"35","author":"E Bultman","year":"2012","unstructured":"Bultman E, de Haar C, van Liere-Baron A, Verhoog H, West RL, Kuipers EJ et al (2012) Predictors of dose escalation of adalimumab in a prospective cohort of Crohn\u2019s disease patients. Aliment Pharmacol Ther 35(3):335\u2013341","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"3675_CR66","first-page":"145","volume":"35","author":"J Rosas","year":"2017","unstructured":"Rosas J, Llinares-Tello F, Senabre-Gallego JM, Barber-Vall\u00e9s X, Santos-Soler G, Salas-Heredia E et al (2017) Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis. Clin Exp Rheumatol 35(1):145\u2013148","journal-title":"Clin Exp Rheumatol"},{"key":"3675_CR67","unstructured":"Maronese CA, Moltrasio C, Genovese G, Marzano AV (2023) Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev Clin Immunol. 1\u201121"},{"issue":"5","key":"3675_CR68","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","volume":"86","author":"A Garg","year":"2022","unstructured":"Garg A, Malviya N, Strunk A, Wright S, Alavi A, Alhusayen R et al (2022) Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian hidradenitis suppurativa foundations. J Am Acad Dermatol 86(5):1092\u20131101","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3675_CR69","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/MIB.0000000000000579","volume":"22","author":"IC Janse","year":"2016","unstructured":"Janse IC, Koldijk MJ, Spekhorst LM, Vila AV, Weersma RK, Dijkstra G et al (2016) Identification of clinical and genetic parameters associated with hidradenitis suppurativa in inflammatory bowel disease. Inflamm Bowel Dis 22(1):106\u2013113","journal-title":"Inflamm Bowel Dis"},{"key":"3675_CR70","first-page":"1","volume":"23","author":"AJ Hendricks","year":"2019","unstructured":"Hendricks AJ, Hsiao JL, Lowes MA, Shi VY (2019) A comparison of international management guidelines for hidradenitis suppurativa. Dermatol Basel Switz 23:1\u201316","journal-title":"Dermatol Basel Switz"},{"issue":"11","key":"3675_CR71","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/jdv.17551","volume":"35","author":"A Hafner","year":"2021","unstructured":"Hafner A, Ghislain PD, Kov\u00e1cs R, Batchelor R, Katoulis AC, Kirby B et al (2021) Improvement in hidradenitis suppurativa and quality of life in patients treated with adalimumab: real-world results from the HARMONY Study. J Eur Acad Dermatol Venereol 35(11):2277\u20132284","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"3675_CR72","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.3390\/biomedicines10102522","volume":"10","author":"M Burlando","year":"2022","unstructured":"Burlando M, Fabbrocini G, Marasca C, Dapavo P, Chiricozzi A, Malvaso D et al (2022) Adalimumab originator vs. biosimilar in hidradenitis suppurativa: a multicentric retrospective study. Biomedicines 10(10):2522","journal-title":"Biomedicines"},{"issue":"9","key":"3675_CR73","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40262-016-0502-4","volume":"56","author":"A Nader","year":"2017","unstructured":"Nader A, Beck D, Noertersheuser P, Williams D, Mostafa N (2017) Population pharmacokinetics and immunogenicity of adalimumab in adult patients with moderate-to-severe hidradenitis suppurativa. Clin Pharmacokinet 56(9):1091\u20131102","journal-title":"Clin Pharmacokinet"},{"issue":"14","key":"3675_CR74","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CLM, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JWR et al (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14):1460\u20138","journal-title":"JAMA"},{"issue":"2","key":"3675_CR75","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3897\/folmed.62.e39402","volume":"62","author":"K Kraev","year":"2020","unstructured":"Kraev K, Geneva-Popova M, Popova V, Popova S, Maneva A, Batalov A et al (2020) Drug-neutralizing antibodies against\u00a0TNF-\u03b1 blockers as biomarkers of therapy effect evaluation. Folia Med (Plovdiv) 62(2):282\u20139","journal-title":"Folia Med (Plovdiv)"},{"issue":"4","key":"3675_CR76","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/09546634.2021.1914309","volume":"33","author":"G Odorici","year":"2022","unstructured":"Odorici G, Pacetti L, Forconi R, Schettini N, Zedde P, Corazza M et al (2022) Seven years-experience of adalimumab therapy for hidradenitis suppurativa in a real-life dermatologic setting. J Dermatol Treat 33(4):2063\u20132067","journal-title":"J Dermatol Treat"},{"key":"3675_CR77","unstructured":"Stylianakis E, Kanni T, Koufargyris P, Giamarellos-Bourboulis EJ (2024) Draining tunnel microbiome in hidradenitis suppurativa: modulation by time-course. Oral communication pr\u00e9sent\u00e9 \u00e0: 13th conference of the European Hidradenitis Suppurativa Foundation (EHSF); 2024 Lyon"},{"issue":"3","key":"3675_CR78","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1159\/000512617","volume":"237","author":"D Stergianou","year":"2021","unstructured":"Stergianou D, Tzanetakou V, Argyropoulou M, Kanni T, Bagos PG, Giamarellos-Bourboulis EJ (2021) Staphylococcus aureus carriage in hidradenitis suppurativa: impact on response to adalimumab. Dermatol Basel Switz 237(3):372\u2013377","journal-title":"Dermatol Basel Switz"},{"issue":"9","key":"3675_CR79","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/ijd.14170","volume":"58","author":"TL Braunberger","year":"2019","unstructured":"Braunberger TL, Lowes MA, Hamzavi IH (2019) Hemoglobin as an indicator of disease activity in severe hidradenitis suppurativa. Int J Dermatol 58(9):1090\u20131091","journal-title":"Int J Dermatol"},{"issue":"3","key":"3675_CR80","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.jaad.2022.08.064","volume":"88","author":"PK Krajewski","year":"2023","unstructured":"Krajewski PK, Jfri A, Ochando-Ibern\u00f3n G, Martorell A (2023) Ultrasonographic railway sign in tunnels as a new independent risk factor of adalimumab failure in hidradenitis suppurativa. J Am Acad Dermatol 88(3):732\u2013734","journal-title":"J Am Acad Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03675-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03675-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03675-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T12:04:37Z","timestamp":1736251477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03675-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3675"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03675-w","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"8 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mathieu Daoud has received support for attending meetings and travel by AbbVie and Novartis, and has received honoraria from AbbVie for presentations, and from Novartis for his participation on an advisory board. Laura Nobile has received support for attending meetings and travel by AbbVie and Novartis. Gregor BE Jemec has received honoraria for participation as an investigator from AbbVie, Novartis, Union Therapeutics, Henlez, Sanofi, UCB, Incyte and Boehringer Ingelheim, for participation on advisory boards from Novartis, UCB, Incyte and Boehringer Ingelheim. V\u00e9ronique del Marmol has received, as payment to her institution, grants or contracts from BMS, MSD, Almirall and Sanofi, consulting fees from BMS, MSD, Novartis, Pierre Fabre, Merck, Sanofi, Almirall, Leo and AbbVie, honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events from BMS, MSD, Sanofi, Sun Pharma, Pierre Fabre and Novartis, and support for attending meetings and travel by BMS, MSD, Pierre Fabre and Novartis. Farida Benhadou, Mariano Suppa, Anne-Sophie Sarkis, St\u00e9phanie Heudens, Lila Desmarest, Hassane Njimi, Mathilde Daxhelet, Jalila Karama and Jonathan M White have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the data used in this study came from the European Registry for Hidradenitis Suppurativa (ERHS), whose project was approved by the Ethics Committee of H\u00f4pital Erasme (Erasme Ethical Committee P2015\/071).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All subjects have given their written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed concent"}}],"article-number":"189"}}